Feb. 1, 2022, 9:49 PM
CV Sciences Inc. traders who say it misled them concerning the patentability of its cannabidiol product requested a federal choose in Nevada for preliminary approval of their $712,500 settlement.
The deal follows three years of “hard-fought” litigation and represents greater than 3.3% of most potential damages, in line with a memo the specialty pharmaceutical firm’s traders filed as a part of their preliminary settlement approval bid within the U.S. District Court docket for the District of Nevada.
“The dangers of additional litigation are exacerbated by CV Sciences’ monetary place,” the investor memo stated. “It’s Lead Plaintiff’s understanding that the Firm’s skill to …
